ArticleInfection and drug resistance2025
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Talaromycosis is an invasive fungal infection caused by the pathogenic fungus Case Presentation: Two cases of talaromycosis in non-endemic areas were retrospectively analyzed. The first case involved a human immunodeficiency virus (HIV)-infected patient with tracheobronchial talaromycosis. Bronchoscopy revealed multiple nodular neoplasms in the trachea and bilateral main bronchi. Histopathological examination of the biopsy tissue showed histiocyte aggregation and intracellular pathogens. Conclusion: Talaromycosis warrants more clinical attention in both HIV-negative individuals and non-endemic areas. In addition, clinicians should improve diagnostic recognition of this disease for timely management. Bronchoscopy combined with mNGS can facilitate early diagnosis of talaromycosis, particularly in culture-negative cases where conventional methods fail. This strategy directly addresses a major diagnostic challenge and improves patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.